China Chemical Pharmaceutical Industry Report, 2013-2016
(PRWEB) June 04, 2014
Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than that of the API over the same period. In 2013, China chemical drug preparation industry and and China API industry recorded revenue of RMB 573.1 billion and RMB 382 billion, with gross margin of 35%-40% and 20%, respectively.
Browse Full Report With Toc: http://www.marketresearchreports.biz/analysis-details/china-chemical-pharmaceutical-industry-report-2013-2016
China is a big producer of chemical APIs, capable of producing about 1,600 varieties of APIs. China ranks first worldwide in output of several bulk APIs including penicillins, vitamins and antipyretic analgesics, and holds a significant share of the featured APIs like statins, prils, sartans in the world. China produced 2.709 million tons of chemical APIs in 2013.
Although China is the world's leading chemical APIs supply region, the concentration of China chemical APIs industry is rather low due to numerous categories of APIs and limited overall strength of domestic enterprises, which occupy an important place only in single or a few categories of pharmaceuticals market. In addition, under the pressure of both environmental protection and industrial upgrading, many large APIs companies in the country are transforming into drug preparation companies through means such as R&D and acquisitions.
To Download Full Report with Toc: http://www.marketresearchreports.biz/sample/sample/206780
North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co., Ltd. are major suppliers of antibiotic and VC APIs in China, with supply of VS reaching around 20,000 tons each. In 2013, the two companies’ total revenue from APIs and their revenue from drug preparation business reached RMB 5.695 billion and RMB 3.871 billion, respectively.
Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are the leading manufacturers of VE products around the globe, with raw materials (vital ingredients for the production of VE are limited raw materials: isophytol and trimethylhydroquinone) for VE being produced by themselves. However, the two companies’ development is constrained due to a weak global demand for VE, of which Zhejiang Medicine reported revenue of RMB 4.915 billion from pharmaceutical business (APIs+ preparation), down 6.3% year on year.
Inquiry Before Buying Report: http://www.marketresearchreports.biz/analysis/206780
Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. are the key suppliers of featured APIs in China, of which the former specializes in antineoplastic and cardiovascular products, and the latter, which obtains three certificates from EDQM in 2013, is a major global supplier of prils and sartans APIs. In 2013, the two companies’ total revenues from APIs and drug preparation business were RMB 3.226 billion and RMB 2.272 billion, rising by 19.5% and 14.7% from the previous year, respectively.
Zhejiang Xianju Pharmaceutical Co., Ltd. and Tianjin Tianyao Pharmaceuticals Co., Ltd. are the leading suppliers of hormone APIs, of which the former has been aggressively expanding into downstream drug preparation business. In the context of stricter environmental standards and rising costs of raw materials, developing the downstream will undoubtedly ensure competitiveness of the company. In 2013, Xianju Pharmaceutical posted total revenue of RMB 2.233 billion from APIs and preparation business, up 16.2% against the prior year. Also in 2013, the company acquired three EDQM certificates for its APIs.
Pharmaceutical Market: Canada-Market Growth, Size, Share and Forecast
Browse Full Report With Toc: http://www.marketresearchreports.biz/analysis-details/the-pharmaceutical-market-canada
THE PHARMACEUTICAL MARKET: CANADA - REVIEW
The relatively high consumption of patented drugs in Canada in comparison with other developed countries remains a positive sign for multinational pharmaceutical companies to maintain their current sales level s by 201 7 . Although innovative drugmakers have also experienced government cost containment policies and the patent cliff in Canada, the negative impact of these phenomena is less extreme than that in many other developed countries. The average cost of generic drugs per prescription experienced its first decline in Canada during 2011, indicating that a more competitive environment for generic drugmakers has been formed, which will ultimately benefit consumers .
Pharmaceuticals: CAD25.81bn (US$26.06bn) in 2011 to CAD25.64bn (US$25.64bn) in 2012; -0.5% growth in local currency terms and -1.6% growth in US dollar terms. ForecastdownwardfromQ412on account oflower than expected new industry data.
MedicalDevices: CAD6.83bn (US$6.91bn) in 2011 to CAD7.12bn (US$7.12bn) in 2012; +4.2% growth in local currency terms and +3.1% growth in US dollar terms. Forecastslightly up fromQ412due to new industry data.
To Download Full Report with Toc: http://www.marketresearchreports.biz/sample/sample/198480
The attractiveness of the Americas to multinational pharmaceuticals has declined moderately in BMI's RRRs for Q113. The average score for the region increased from 49.2 in Q412 to 49.4 in Q113. The Americas region continues to rank second-lowest globally with a score of 49.4 out of 100, behind Western Europe (66), Asia Pacific (53) and Central and Eastern Europe (51), but ahead of the Middle East and Africa (44).
Global And Chinese Erlotinib Hydrochloride Industry, 2009-2019-Industrial Growth, Size, Share, Investment and Forecast
Market Research Report on Global and Chinese Erlotinib hydrochloride Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Erlotinib hydrochloride industry. The report firstly reviews the basic information of Erlotinib hydrochloride including its classification, application and manufacturing technology; The report then explores global and Chinas top manufacturers of Erlotinib hydrochloride listing their product specification, capacity, Production value, and market share etc.; The report further analyzes quantitatively 2009-2014 global and Chinas total market of Erlotinib hydrochloride by calculation of main economic parameters of each company; The breakdown data of Erlotinib hydrochloride market are presented by company, by country, and by application; The report also estimates 2014-2019 market development of Erlotinib hydrochloride Industry.
The report then analyzes the upstream raw materials, downstream clients, and current market dynamics of Erlotinib hydrochloride Industry. In the end, the report makes some proposals for a new project of Erlotinib hydrochloride Industry and a new project of Erlotinib hydrochloride Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2009-2014 global and China Erlotinib hydrochloride industry covering all important parameters.
To Download Full Report with Toc:
Table of Contents
Chapter One Introduction of Erlotinib hydrochloride Industry
1.1 Brief Introduction of Erlotinib hydrochloride
1.2 Development of Erlotinib hydrochloride Industry
1.3 Status of Erlotinib hydrochloride Industry
Chapter Two Manufacturing Technology of Erlotinib hydrochloride
2.1 Development of Erlotinib hydrochloride Manufacturing Technology
2.2 Analysis of Erlotinib hydrochloride Manufacturing Technology
2.3 Trends of Erlotinib hydrochloride Manufacturing Technology
Chapter Three Analysis of Global Key Manufacturers (Including Company Profile, Product Specification, 2009-2014 Production Information etc.)
3.1 Company A
3.2 Company B
3.3 Company C
3.4 Company D
3.5 Company E
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Office: United States
90 State Street, Suite 700
Albany, NY 12207
Toll Free: 866-997-4948